Edwards Lifesciences Corp (EW)
A global provider of products and technologies designed to treat advanced cardiovascular disease. The Company focuses on specific cardiovascular opportunities including heart valve disease, peripheral vascular disease and critical care technologies.
Recs
LyndaGayl
(26.06)
Submitted: 11/3/2009 10:27:01 AM :
Start Price:
$77.43
EW Score:
-1.41
On my screener as a short.
Recs
mrbill6
(< 20)
Submitted: 10/20/2009 2:37:32 PM :
Start Price:
$71.27
EW Score:
+15.40
navallier.investorplace.com rated: A and moneycentral.msn.com rated:9
Recs
marrd
(84.26)
Submitted: 3/23/2009 12:52:33 PM :
Start Price:
$60.86
EW Score:
-2.61
One acronym says it all: THV. Edwards' SAPIEN Transcatheter Heart Valve is a revolutionary new heart valve surgery which makes it possible to replace a diseased valve without cracking the chest. In the short term, this allows patients who would otherwise die during invasive surgery (or in absence of surgery) another chance at life. In the long run, further innovation opens up use of the technology as a cosmetic advantage over open heart surgery. This device has been going through clinical trials in Europe on its way to FDA approval, and faces competition from similar valve replacement approaches by companies such as Medtronic (who recently bought CoreValve). EW is an estimated 2 years further along the track for FDA approval, which will give it the cushion it needs to generate a solid foothold in the market before competitive products are launched, allowing its revenue to grow at an impressive rate in the coming years.
Recs
Recs
jlmjlm77
(99.81)
Submitted: 8/26/2008 2:33:29 PM :
Start Price:
$58.23
EW Score:
-52.52
Inside selling
Recs
robo2011
(99.32)
Submitted: 7/20/2008 11:32:25 PM :
Start Price:
$66.25
EW Score:
-35.14
Overvalued and at the top of a 52 week high, this stock is ripe and ready for a fall.
Recs
jetlith
(65.54)
Submitted: 7/3/2008 4:06:35 PM :
Start Price:
$61.58
EW Score:
-44.85
gone up wayyyyyy too high, especially in this bear market.. and YoY eps has been dropping big. I expect a correction back down to the 40's.
Recs
ScreenerStizBear
(28.75)
Submitted: 6/26/2008 2:29:59 PM :
Start Price:
$62.29
EW Score:
-44.76
I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!
Recs
socalsy
(95.49)
Submitted: 5/6/2008 1:51:41 PM :
Start Price:
$55.50
EW Score:
-68.37
Its recent runup makes it overvalued. It would have to grow earnings over 21% a year for the next 5 years to justify $55/share.
Recs
joelima
(< 20)
Submitted: 4/11/2008 4:08:21 PM :
Start Price:
$46.24
EW Score:
+92.75
Great pipeline
Recs
ll0o0ll
(98.18)
Submitted: 5/21/2007 10:49:14 AM :
Start Price:
$49.69
EW Score:
+90.25
Terrific company ttat pursue a technology to allow cardio vault placement without major surgery.
Recs
NetscribeMedDevs
(91.28)
Submitted: 2/26/2007 7:51:36 AM :
Start Price:
$51.85
EW Score:
+79.40
Cardiovascular diseases is the number one cause of death world wide and is among the top three diseases in terms of health care spending in nearly every country. In the U.S. alone it is slated to affect 7 million people annually and the number is more or less same in countries around the world. Edward life systems operate in this area providing products and technology that caters to advanced cardiovascular diseases.
The company operates through five product lines namely Heart valve therapy, Critical care, Cardiac Surgery system, Vascular and other distribution products. The company is the market leader in the $1.1 billion heart valve market, which contributes about 48% of total revenue. Critical care chips in with 32% and the rest three segments contribute the rest almost equally. The company also has a spread out geographical presence with revenues coming from North America, Europe, Japan and Other International Markets in the proportion 50%, 22%, 18% and 10% respectively.
The heart valve market is undergoing a shift from mechanical valves to tissue-based valves, which strengthens Edward’s position, as the company is traditionally strong in the segment. The market for such valves is expect to grow at 7% annual, but Edward’s unique position puts it in a 9% per annum growth track as it has a first mover advantage. Also Stent products are going to revolutionalise the manner, in which cardiovascular diseases are treated, and the company with new products introduced in this segment is trying to make the most of the opportunity. The future thus looks promising for the company, as they have caught the tide at the right time and at the right place. Now all that is left is to sail the course.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 12 of 12